Pages that link to "Q54323561"
Jump to navigation
Jump to search
The following pages link to Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. (Q54323561):
Displaying 50 items.
- Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review (Q26750470) (← links)
- Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives (Q26751274) (← links)
- The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer (Q26795503) (← links)
- Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer (Q26862841) (← links)
- Medical management of metastatic medullary thyroid cancer (Q27005897) (← links)
- Neoadjuvant Therapy in Differentiated Thyroid Cancer (Q28078879) (← links)
- GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. (Q33397349) (← links)
- Hereditary endocrinopathies (Q33734828) (← links)
- A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome (Q34035391) (← links)
- Thyroid nodules and thyroid cancer: surgical aspects. (Q34108480) (← links)
- Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers (Q34123724) (← links)
- Papillary thyroid cancer (Q34678715) (← links)
- Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Q34758477) (← links)
- Thyroid cancer--remaining problems (Q35145724) (← links)
- Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution (Q35252958) (← links)
- Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer (Q35295368) (← links)
- Standard and emerging therapies for metastatic differentiated thyroid cancer (Q35583906) (← links)
- Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease (Q35864072) (← links)
- The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy. (Q35872419) (← links)
- Evolving approaches to patients with advanced differentiated thyroid cancer (Q36864736) (← links)
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study (Q36877022) (← links)
- Phase II trial of sorafenib in advanced thyroid cancer (Q37121708) (← links)
- New agents in the treatment for malignancies of the salivary and thyroid glands (Q37137859) (← links)
- Remarkable response in 2 cases of Advanced Poorly Differentiated Thyroid Carcinoma with liposomal doxorubicin plus cisplatin (Q37187761) (← links)
- Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience (Q37417441) (← links)
- Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements (Q37505185) (← links)
- Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment (Q37599227) (← links)
- Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor (Q37624473) (← links)
- Novel molecular targeted therapies for refractory thyroid cancer (Q37872269) (← links)
- Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury (Q38166071) (← links)
- Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy (Q38243095) (← links)
- Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer (Q38823954) (← links)
- The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies (Q38865611) (← links)
- Chemotherapy of skeletal metastases (Q39408201) (← links)
- Advances in the diagnosis and treatment of medullary thyroid carcinoma. (Q39462141) (← links)
- Adriamycin in advanced urinary tract cancer.Experience in 42 patients and review of the literature (Q39616770) (← links)
- Management of Carcinoma of the Thyroid (Q39617574) (← links)
- Neoplasms of Endocrine Glands (Q39620082) (← links)
- Advances in rational combination chemotherapy (Q39754159) (← links)
- 15 Treatment of thyroid cancer (Q39790578) (← links)
- Therapy of malignant APUD cell tumors: Effectiveness of DTIC (Q40132855) (← links)
- Management of the patient with progressive radioiodine non-responsive disease (Q40828601) (← links)
- pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer. (Q40844396) (← links)
- Medullary thyroid carcinoma.Importance of serial serum calcitonin measurement (Q41486585) (← links)
- Multiple Endocrine Neoplasia Type IIb: The Most Aggressive Form of Medullary Thyroid Carcinoma (Q41591754) (← links)
- Emerging role of multikinase inhibitors for refractory thyroid cancer (Q41837863) (← links)
- Response of undifferentiated thyroid carcinoma to combined modality treatment (Q41899075) (← links)
- Significant Amelioration of Tracheal Stenosis following Lenvatinib in a Patient Who Has Anaplastic Thyroid Carcinoma with Bronchomediastinal Infiltration: A Case Report (Q41954414) (← links)
- Progress in Endocrine Neoplasia (Q42285779) (← links)
- Prognosis of undifferentiated carcinoma and lymphoma of the thyroid (Q43467001) (← links)